Anbio Biotechnology (NNNN) Change in Account Payables (2024 - 2025)

Anbio Biotechnology (NNNN) recorded quarterly Change in Account Payables of $60.4 billion in Q2 2025, down 96.29% quarter-over-quarter from $1625.3 billion in Q4 2024.

Anbio Biotechnology (NNNN) Change in Account Payables (2024 - 2025) Analysis & Trends

Anbio Biotechnology's Change in Account Payables history runs 2 years deep, the most recent figure standing at $60.4 billion for Q2 2025.

  • In Q2 2025, Change in Account Payables changed N/A year-over-year to $60.4 billion; the TTM figure through Jun 2025 stood at $60.4 billion (changed N/A YoY), while the FY2025 annual figure was -$1.6 million, down 100.0% from the prior year.
  • Change in Account Payables was $60.4 billion for Q2 2025 at Anbio Biotechnology, down from $1625.3 billion in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1625.3 billion in Q4 2024 to a low of $60.4 billion in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Intuitive Surgical 148.09 Bn 143.69 Bn 1.83 Bn 73.90 Mn
2 Becton Dickinson 41.00 Bn 39.99 Bn 2.15 Bn -
3 Medline 30.38 Bn 36.22 Bn 1.84 Bn 6.00 Mn
4 Resmed 28.22 Bn 26.56 Bn 890.98 Mn -
5 West Pharmaceutical Services 23.72 Bn 23.19 Bn 296.40 Mn -
6 Solventum 13.33 Bn 13.33 Bn 1.10 Bn 23.00 Mn
7 Cooper Companies 13.12 Bn 12.99 Bn 735.40 Mn -
8 Align Technology 12.86 Bn 11.80 Bn 736.59 Mn 4.93 Mn
9 Baxter International 10.51 Bn 8.47 Bn 891.00 Mn 102.00 Mn
10 Anbio Biotechnology 720.59 Mn 708.69 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 60.35 Bn
Jun 30, 2025 60.35 Bn
Dec 31, 2024 1,625.26 Bn
Dec 31, 2024 1,625.26 Bn